Northwire Canada EditionSunday, July 12, 2026
Northwire
GLDN 0.055 +0.0% BRON 0.040 +0.0% BTO 5.43 −0.7% ESK 0.365 −2.7% AUMN 0.275 +0.0% GGX 0.040 +0.0% S 0.155 +29.2% NNX 0.035 +0.0% ABX 51.90 −0.6% TTS 2.40 −4.0% FCI 0.400 −9.1% GR 0.075 +0.0% AII 23.38 +12.4% TUNG 1.72 +1.8% LGO 1.01 −2.9% EMM 0.080 +0.0% GLDN 0.055 +0.0% BRON 0.040 +0.0% BTO 5.43 −0.7% ESK 0.365 −2.7% AUMN 0.275 +0.0% GGX 0.040 +0.0% S 0.155 +29.2% NNX 0.035 +0.0% ABX 51.90 −0.6% TTS 2.40 −4.0% FCI 0.400 −9.1% GR 0.075 +0.0% AII 23.38 +12.4% TUNG 1.72 +1.8% LGO 1.01 −2.9% EMM 0.080 +0.0%
Financings

Avicanna Announces Closing of Non-Brokered Private Placement

AVCN · Price

Executive Summary

  • Avicanna Inc. closed a non‑brokered private placement raising $1,550,000 in gross proceeds.
  • The offering consisted of 7,750,001 units priced at $0.20 per unit, each unit containing one common share and half of a warrant to purchase an additional share at $0.25.
  • Proceeds will be used for general working capital, administrative expenses, production/manufacturing costs, and research & clinical development.

Key Details

  • Units Offered: 7,750,001 units @ $0.20 per unit = $1,550,000 gross proceeds.
  • Unit Composition:
  • 1 common share (Unit Share)
  • 0.5 of a common‑share purchase warrant (each whole warrant allows purchase of 1 share at $0.25).
  • Warrant Terms: Exercise price $0.25 per share, exercisable until February 10, 2029; subject to adjustment in certain events.
  • Holding Period: Unit Shares and Warrants are subject to a four‑month hold period under Canadian securities laws.
  • Closing Conditions: Completion pending all required approvals, including Toronto Stock Exchange approval.
  • Use of Proceeds: Allocation to:
  • General working capital
  • General & administrative expenses
  • Production and manufacturing expenditures
  • Research and clinical development activities

Notable Quotes

(No direct quotes were provided in the release.)

Read the original news release →

More from AVICANNA INC. J